The neonatal Fc receptor for IgG (FcRn) is responsible for the transfer of passive humoral immunity from the mother to the newborn in rodents and humans. Throughout life, FcRn contributes to effective ...

Immunovant’s decision to prioritize a next-gen FcRn antibody over phase 3 myasthenia gravis (MG) prospect batoclimab means Vyvgart’s crown remains secure for the time being, analysts have concluded.

The unveiling of Johnson & Johnson’s full data from the phase 2 trial of nipocalimab in Sjögren's disease (SjD) suggest that both the Big Pharma and its competitor argenx are on the right track by ...

Medications targeting the neonatal fragment crystallizable receptor have gained attention due to multiple recent FDA ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...

These data represent the first positive results of an investigational FcRn blocker treatment in this chronic, debilitating autoantibody-driven disease that impacts an estimated 3 to 5 million people ...

The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting treatments for generalized myasthenia gravis (gMG) in adults. The phase ...

Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering ...

Immunovant listed on Nasdaq in 2019 through a SPAC with Roivant Sciences as majority owner, focusing on developing drugs for autoimmune diseases, notable the FcRn inhibitor batoclimab. Batoclimab, ...

Ray Lambert looks at the potential of humanized FcRn mice for evaluating the pharmacokinetics of mAbs. Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human immunoglobulin ...